Nuclithera
Targeted radiopharmaceuticals for patients with metastatic and difficult-to-treat cancers
Highlights
- Young companyFounded 2023
- New on EvolcAdded 2026-10-28
About Nuclithera
NucliThera develops targeted alpha- and beta-radiation therapies by pairing radionuclides with cancer-specific targeting molecules. Its pipeline includes treatments for solid tumors and hematological cancers, as well as a proprietary lead-212 generator.
The company is a Norwegian biotechnology company founded in 2023 and headquartered in Oslo. It has specialized laboratories authorized for radiation work and a scientific team spanning drug development, radiochemistry, biology and clinical development.
Product: Targeted alpha- and beta-radiation therapies for cancer, a proprietary lead-212 generator, and a CD37 platform.
Jobs at Nuclithera
Leadership
- Morten Lande · Founder-Board memberSource: company website
- Ludvik Sandness · CEO - Board MemberSource: company website
- Øyvind Bruland · CMO - FounderSource: company website
- Roy H. Larsen · CTO - Founder, Chairman of the BoardSource: company website
More biotech & pharma companies
Nykode Therapeutics
Develops immunotherapies for patients with cancer and autoimmune diseases using a modular biotech platformNew on EvolcOncosyne
Tumoroid-based drug screening and predictive diagnostics for pharmaceutical companies and cancer care providersNew on EvolcPharma Holdings
Develops intranasal antimicrobial drugs for patients with respiratory viral infectionsNew on EvolcPluvia
Develops small-molecule drugs for patients with rare protein-misfolding disorders, starting with phenylketonuria (PKU)New on EvolcPreviwo
Probiotic products for farmed salmon and trout that strengthen fish health in aquacultureNew on EvolcProphylaxia
Researches salmon signalling substances such as SNAP as a sea lice alternative for salmon farmingNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- PHP
- WordPress